Leerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45
Leerink Partners analyst Daniel Clark initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $45.
A research team that studies companies just started following Collegium Pharmaceutical and thinks it looks good. This means experts believe the company has a promising future, so it's worth paying attention to what happens next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.